In February, Novartis sold most of its listed Indian unit but kept its unlisted arm focused on cutting-edge medicines.
With over 9,000 employees here and development hubs in Hyderabad and Mumbai (alongside Basel and the U.S.), India has helped deliver important treatments like Coartem Baby and Inclisiran.
Novartis says it's committed to bringing even more new therapies from India to the world.